An observational study in End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD), sponsored by Vantive Health LLC. Recruiting at 20 sites in China. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Vantive Health LLC (formerly part of Baxter Healthcare Corporation) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation — 1 open to participants now, 1 under way, none of them phase 3. Kidney Failure, Chronic · Baxter Healthcare Corporation.
Among the 34 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation, this one is the only one that started in 2026, is one of 5 observational ones, and was the 34th registered.
2,109 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →1 of the 34 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation is open now, in 1 country.
By country, each count listing its studies:
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 750 is above the median of 120 across 443 observational studies indexed under Kidney Failure, Chronic.
Median enrollment 43 across the 29 interventional studies, 76 across the 5 observational. Of the 31 that completed or were terminated, 7 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Vantive Health LLC, one of the names counted as Baxter Healthcare Corporation. Under that name alone:
Vantive Health LLC is the lead sponsor of 55 studies on the registry; 3 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, prospective, observational real-world study designed to evaluate clinical effectiveness, quality of life, and healthcare resource utilization in patients with end-stage renal disease (ESRD) initiating dialysis therapy in China.
Participants will be grouped according to the dialysis modality selected through routine clinical practice and shared decision-making with their treating physicians: remote patient monitoring-assisted automated peritoneal dialysis (RPM-APD), manual peritoneal dialysis (PD), or maintenance hemodialysis (HD). No study-specific interventions will be assigned.
The study will compare outcomes across these cohorts, including quality of life, social reintegration, clinical outcomes (e.g., complications and survival), and healthcare resource utilization. Propensity score matching will be applied to adjust for baseline differences between cohorts.
This study plans to screen Chinese patients receiving remote patient monitoring-automated peritoneal dialysis (RPM-APD), manual peritoneal dialysis (manual PD), or maintenance hemodialysis (HD). Each patient must meet all inclusion criteria and none of the exclusion criteria for this study. No exceptions are permitted under any circumstances.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Remote patient monitoring-automated peritoneal (RPM-APD)
Device: Manual peritoneal dialysis (PD) cohort
Device: Maintenance hemodialysis (HD)
RPM-APD refers to peritoneal dialysis performed at home using an APD cycler, with the prescription, treatment process, monitoring, and management conducted via a remote management system.
Manual PD refers to home-based dialysis exchange therapy performed by the patient/caregiver according to the physician's prescription without the use of automated equipment.
Maintenance HD refers to conventional hemodialysis therapy performed by professional staff in a dialysis center/hemopurification unit, initiated after the induction dialysis period.
Patient survival rates
Time frame: 6, 12, and 24 months
Quality of Life Scores (EQ-5D-5L)
Change in quality of life scores measured using the EuroQol Five Dimensions (EQ-5D-5L) scales
Time frame: 6, 12 and 24 months
Quality of Life Scores (KDQOL-36)
Change in quality of life scores measured using the Kidney Disease Quality of Life-36 (KDQOL-36)
Time frame: 6, 12, and 24 months
Social Reintegration
Social functioning and reintegration assessed using the Work and Social Adjustment Scale (WSAS)
Time frame: 6, 12, and 24 months
Social Reintegration
Social functioning and reintegration assessed using the EQ-5D-5L
Time frame: 6, 12 and 24 months
Social Reintegration
Social functioning and reintegration assessed using supplementary questionnaires
Time frame: 6, 12 and 24 months
Healthcare Resource Utilization (Direct Medical Costs)
Assessment of healthcare resource utilization including hospitalization rate
Time frame: 6, 12, and 24 months
Healthcare Resource Utilization (Direct Medical Costs)
Assessment of healthcare resource utilization including number of hospitalizations
Time frame: 6, 12, and 24 months
Healthcare Resource Utilization (Direct Medical Costs)
Assessment of healthcare resource utilization including length of hospital stay
Time frame: 6, 12, and 24 months
Healthcare Resource Utilization (Direct Medical Costs)
Assessment of healthcare resource utilization including outpatient and emergency visits
Time frame: 6, 12, and 24 months
Healthcare Resource Utilization (Direct Medical Costs)
Assessment of healthcare resource utilization including total hospitalization costs
Time frame: 6, 12, and 24 months
Healthcare workforce utilization
Time and resource utilization by healthcare providers per patient including remote communication collected via healthcare staff questionnaire
Time frame: 6, 12, and 24 months
Healthcare Resource Utilization (Direct Non-Medical Costs and Indirect Costs)
Costs related to non-medical expenditures and productivity loss collected via patient questionnaires
Time frame: 6, 12, and 24 months
Incidence of infection-related complications
Infection related complications including but not limited to peritonitis, pulmonary infections, peritoneal dialysis catheter-related infections, hemodialysis catheter-related infections, and urinary tract infections.
Time frame: 1, 3, 6, 12, 18, and 24 months
Incidence of cardiovascular and cerebrovascular events
Cardiovascular events include but are not limited to acute myocardial infarction, angina, sudden cardiac death, heart failure, arrhythmia and other ischemic heart diseases. Cerebrovascular events include but are not limited to stroke, cerebral hemorrhage, and peripheral arterial disease.
Time frame: 1, 3, 6, 12, 18, and 24 months
Incidence of dialysis access-related complications
dialysis access-related complications including access-related infections and dysfunction for both PD and HD: Peritoneal dialysis catheter-related infections, Peritoneal dialysis catheter dysfunction, Hemodialysis access-related infections and Hemodialysis access dysfunction
Time frame: 1, 3, 6, 12, 18, and 24 months
Change from baseline in 24-hour urine output
For PD patients, 24-hour urine volume data is collected during dialysis adequacy assessment. For HD patients, 24-hour urine volume is the average volume over two consecutive days (a dialysis day and a non-dialysis day).
Time frame: 3, 12, and 24 months
Dialysis quality control indicators
The rate of achieving the standard for small molecule solute clearance
Time frame: 6, 12, and 24 months
Dialysis quality control indicators
Hypertension control rate: The proportion of maintenance HD or PD patients meeting the blood pressure control targets during the assessment period
Time frame: 6, 12, and 24 months
Dialysis quality control indicators
Renal anemia control rate: The proportion of maintenance HD or PD patients with hemoglobin (Hb) levels ≥ 110 g/L during the assessment period
Time frame: 6, 12, and 24 months
Dialysis quality control indicators
CKD-Mineral and Bone Disorder (CKD-MBD) indicators control rate: The proportion of maintenance HD or PD patients meeting the control standards for CKD-MBD indicators during the assessment period
Time frame: 6, 12, and 24 months
Dialysis quality control indicators
Serum albumin control rate: The proportion of maintenance HD or PD patients with serum albumin levels ≥ 35 g/L during the assessment period
Time frame: 6, 12, and 24 months
Proportion of patients transferred to HD
Transferred to HD is defined as transfer from PD to HD for ≥ 30 consecutive days
Time frame: 6, 12, and 24 months
Ultrafiltration volume and solute clearance
Collection of data from dialysis adequacy assessment including 24-hour ultrafiltration volume
Time frame: 3, 12, and 24 months
Ultrafiltration volume and solute clearance
Collection of data from dialysis adequacy assessment including weekly residual renal Kt/V, weekly dialysis Kt/V, and weekly total Kt/V
Time frame: 3, 12, and 24 months
Ultrafiltration volume and solute clearance
Collection of data from dialysis adequacy assessment including weekly residual renal creatinine clearance (Ccr), weekly dialysis Ccr, and weekly total Ccr.
Time frame: 3, 12, and 24 months
Change from baseline in blood pressure
Office blood pressure (OBP), defined as blood pressure (systolic and diastolic) measured in a healthcare setting by a physician, nurse, or other trained professional using a validated sphygmomanometer.
Time frame: 1, 3, 6, 12, 18, and 24 months
Started Jun 2026 (actual). Primary completion is estimated for Jun 2029, 36 months after the start.
Of 150 observational studies under Kidney Failure, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 62. This study's planned 36 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.